How does the FDA evaluate HRT safety today

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA evaluates HRT safety by reviewing scientific evidence from clinical trials, monitoring real-world data after products reach the market, and updating warnings or requirements whenever new risks or benefits become clear. The FDA focuses on dose, route, and duration to assess whether benefits outweigh risks for the indicated population.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How the FDA Reviews HRT Before Approval

According to FDA.gov, the FDA requires companies to submit rigorous research before any hormone product is approved. This includes:

• Clinical trials: Studies in humans that evaluate how well the hormone works and what side effects may appear at different doses and forms.
• Safety labs and imaging: Data on blood pressure, clotting factors, breast changes, and metabolic markers.
• Product consistency: Proof that every dose, patch, or cream delivers a stable, predictable amount of hormone.

According to FDA-approved prescribing information for commercially available HRT products, the FDA evaluates risks that appeared in past research — such as blood clots, stroke, and breast cancer — and requires that trials specifically look for early warning signs.

How the FDA Monitors HRT After Approval

According to FDA.gov, once a product is on the market, the FDA continues to monitor its safety through:

• Post-marketing reports: Doctors, patients, and pharmacists may report concerns, which the FDA continuously reviews.
• Required long-term studies: Some manufacturers must study real-world use to track rare risks.
• Label updates: If new evidence emerges, the FDA may adjust warnings, add safety information, or guide clinicians toward safer dosing.

This is why labeling for HRT products may change over the years. According to FDA Drug Safety Communications, these updates reflect ongoing evaluation of emerging data, not arbitrary regulatory changes.

What the FDA Prioritizes When Determining Safety

• Lowest effective dose: According to FDA-approved prescribing information, the FDA evaluates whether women receive only the amount needed to relieve symptoms.
• Shortest appropriate duration: According to NAMS, using the minimal time needed while supporting quality of life is a key principle in hormone therapy evaluation.
• Route of delivery: According to FDA.gov, differences between pills, patches, gels, or vaginal forms are evaluated to assess benefits relative to clotting risk.
• Population differences: According to the WHI, age, time since menopause, and health history may change an individual's risk profile.

According to FDA.gov, the FDA's approach is shaped by decades of accumulated data and ongoing post-market surveillance. A qualified prescriber should be consulted to determine whether any hormone therapy option is appropriate for an individual patient's circumstances.